Neuromuscular complications of statins

Physical Medicine and Rehabilitation Clinics of North America
Sung C Ahn

Abstract

Statins, 3-hydroxy-3-methlglutaryl coenzyme A reductase inhibitors, are commonly prescribed for patients who have hyperlipidemia. Statins were first approved in 1987. Statin therapy is well documented to reduce serum low-density lipoprotein levels, incidence of cardiovascular events, and mortality. Although statin therapy is well tolerated, serious adverse affects have been reported, including neuromuscular and hepatic complications. Myopathy is particularly concerning because of the potential for rhabdomyolysis and death. Recently, peripheral neuropathy also has been identified as a possible complication. The incidence of neuromuscular complications is expected to increase with the increased number of people using statin therapy. Clinicians should be aware of the potential neuromuscular complications. This article reviews epidemiology, possible mechanisms, risk factors, and management of statin-associated neuromuscular complications.

References

Feb 1, 1990·Nature·J L Goldstein, M S Brown
Oct 10, 1997·Metabolism: Clinical and Experimental·P D ThompsonJ R Guyton
May 20, 1998·Clinical Pharmacology and Therapeutics·T KantolaP J Neuvonen
Mar 22, 2002·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·E G Bliznakov
May 16, 2002·Neurology·D GaistS H Sindrup
Jul 13, 2002·Journal of Cellular Physiology·M MacalusoA Russo
Jul 20, 2002·Journal of Cardiovascular Pharmacology·Helmut SinzingerBernhard A Peskar
Aug 2, 2002·Current Opinion in Lipidology·Marc Evans, Alan Rees
Aug 21, 2002·Circulation·Richard C PasternakUNKNOWN National Heart, Lung and Blood Institute
Sep 7, 2002·Stroke; a Journal of Cerebral Circulation·Richard C PasternakUNKNOWN National Heart, Lung and Blood Institute
Oct 2, 2002·Annals of Internal Medicine·Paul S PhillipsUNKNOWN Scripps Mercy Clinical Research Center
Oct 19, 2002·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Thomayant PrueksaritanontJiunn H Lin
Mar 8, 2003·Archives of Internal Medicine·Christie M BallantyneEvan A Stein
Mar 18, 2003·Archives of Internal Medicine·C Christopher SmithRobert H Shmerling
Apr 4, 2003·JAMA : the Journal of the American Medical Association·Paul D ThompsonRichard H Karas
Jul 16, 2003·The American Journal of Cardiology·Peter H JonesUNKNOWN STELLAR Study Group
Feb 26, 2004·Neurology·Jens P Dreier, Matthias Endres
Mar 5, 2004·JAMA : the Journal of the American Medical Association·Frank M Sacks
Mar 10, 2004·The American Journal of Medicine·Robert S Rosenson
Mar 17, 2004·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Tina KoumisLorraine A Cicero
Jun 17, 2004·Circulation·Stefano BellostaAlberto Corsini
Jun 23, 2004·British Journal of Clinical Pharmacology·Jari J LiljaPertti J Neuvonen
Oct 6, 2004·Pharmacotherapy·Pang H ChongRussell E Bartt
Dec 2, 2004·JAMA : the Journal of the American Medical Association·David J GrahamRichard Platt
Dec 28, 2004·The American Journal of Cardiology·Peter H Jones, Michael H Davidson
Mar 12, 2005·Archives of Physical Medicine and Rehabilitation·Jeffrey A StrommenIra G Rashbaum
Jul 9, 2005·Clinical Pharmacology and Therapeutics·Hannu PäiväReijo Laaksonen
Aug 12, 2005·Muscle & Nerve·A Arturo LeisJake Olivier
Oct 13, 2005·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Marius TrøseidSigurd Lindal
Oct 21, 2005·British Journal of Clinical Pharmacology·Hitoshi AndoAkio Fujimura
Nov 16, 2005·Archives of Neurology·Costanza LampertiSalvatore DiMauro
Dec 14, 2005·Archives of Internal Medicine·Karen E HansenJames H Stein
Apr 4, 2006·The American Journal of Cardiology·Malcolm Law, Alicja R Rudnicka
Apr 4, 2006·The American Journal of Cardiology·Paul D ThompsonUNKNOWN National Lipid Association Statin Safety Task Force Muscle Safety Expert Panel
Aug 4, 2006·American Journal of Physiology. Cell Physiology·Amie J Dirks, Kimberly M Jones
Aug 18, 2006·Journal of the American Pharmacists Association : JAPhA·Robert L Talbert
Dec 21, 2006·Clinical Pharmacology and Therapeutics·Pertti J NeuvonenJanne T Backman
Jan 11, 2007·Clinical Therapeutics·Anders G Olsson

❮ Previous
Next ❯

Citations

Jun 10, 2008·Expert Opinion on Emerging Drugs·Rebecca L PollexRobert A Hegele
Nov 9, 2010·Journal of the Neurological Sciences·Beatrice NefussyVivian E Drory
Aug 21, 2013·Pharmacoepidemiology and Drug Safety·J Bradley LaytonAbhijit V Kshirsagar
Jun 27, 2012·Neurological Research·Svetlana I Kostic DedicDragana Lavrnic
May 16, 2012·Social Work in Health Care·Juanne N Clarke, Laura Lang
Jun 5, 2017·Metabolic Brain Disease·Seyed Soheil Saeedi SaraviAhmad Reza Dehpour
Feb 26, 2021·Journal of Clinical Pharmacy and Therapeutics·Miao WangYing Xie

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.